Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.
Across the 68 markets, sales in the PAH market were $10.1 billion in 2024, growing to $17.9 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 24.5% and 48.0% in 68-market sales in 2024 and 2034, respectively.
Scope
- In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM PAH therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PAH therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Topics Covered:
1 Executive Summary
1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology
2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders and payers interviewed for this report
2.3.1 Key opinion leaders
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Therapy Area Director
2.5.2 Vice President of Disease Intelligence and Epidemiology
2.5.3 Global Head of Pharma Research, Analysis, and Competitive Intelligence
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Acceleron Pharma Inc
- Actelion
- Amgen Inc
- Bayer AG
- Bristol Myers Squibb
- Eli Lilly and Co
- Entera Bio Ltd
- Gilead Sciences Inc
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co Inc
- Novartis International AG
- Pfizer Inc
- Roche Holding AG
- Sanofi
- Teva Pharmaceutical Industries Ltd
- UCB S.A.
For more information about this report visit https://www.researchandmarkets.com/r/vdwmyp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
